Gastrointestinal · Research Phase
Glucagon Receptor Antagonist Peptides
No lawful US pathway
01 · Overview
Glucagon receptor antagonist peptides are molecules designed to block the glucagon receptor and prevent glucagon-driven hepatic glucose output. Most are modified glucagon analogues in which specific substitutions, such as removal of histidine 1 and replacement of aspartate 9, preserve receptor binding while abolishing activation (PMID 2560175).
The therapeutic rationale is that elevated glucagon contributes to hyperglycemia in diabetes, so blocking its receptor could reduce hepatic gluconeogenesis and glycogenolysis (PMID 25674162). Other glucagon receptor blockers include small molecules and monoclonal antibodies.
02 · Research summary & key findings
In animal studies, peptide antagonists lowered blood glucose: a modified glucagon analogue reduced hyperglycemia in streptozotocin-diabetic rats (PMID 6278587), and des-His1[Glu9]glucagon amide blocked glucagon-induced hyperglycemia in rabbits and reduced hyperglycemia in diabetic rats (PMID 2560175). Clinical testing of glucagon receptor blockade has used non-peptide agents: the small molecule LY2409021 lowered HbA1c but increased liver fat, liver enzymes, and blood pressure in type 2 diabetes (PMID 28371155), and MK-0893 raised LDL cholesterol (PMID 26373568). The antibody volagidemab reduced HbA1c in type 1 diabetes but also raised transaminases and LDL cholesterol (PMID 36192552). No peptide antagonist is known to have entered clinical trials.
03 · Regulatory status
Glucagon Receptor Antagonist Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Glucagon Receptor Antagonist Peptides is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 7 FDA-approved compounds in Gastrointestinal
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Subcutaneous injection
References
- [1]Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist Peptides, 1989. PMID 2560175
- [2]Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus Open Med Chem J, 2014. PMID 25674162
- [3]Glucagon receptor antagonism induces increased cholesterol absorption J Lipid Res, 2015. PMID 26373568
- [4]Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes Diabetes Obes Metab, 2017. PMID 28371155
- [5]Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial Nat Med, 2022. PMID 36192552
- [6]Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist Science, 1982. PMID 6278587
Primary literature
- PubMed: "Glucagon Receptor Antagonist Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Glucagon Receptor Antagonist Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem: "Glucagon Receptor Antagonist Peptides"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Gastrointestinal
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.